Comparative Pharmacology
Head-to-head clinical analysis: VALACYCLOVIR HYDROCHLORIDE versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALACYCLOVIR HYDROCHLORIDE versus VEKLURY.
VALACYCLOVIR HYDROCHLORIDE vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valacyclovir hydrochloride is a prodrug of acyclovir. After oral administration, it is rapidly converted to acyclovir, which inhibits viral DNA polymerase, leading to chain termination and inhibition of viral DNA replication.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
500 mg orally twice daily for recurrent genital herpes; 1 g orally twice daily for herpes zoster; 1 g orally three times daily for herpes simplex encephalitis or immunocompromised patients.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.3 hours in patients with normal renal function; prolonged to 14 hours in renal impairment (CrCl 15–30 mL/min).
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Renal excretion: >90% as unchanged drug and inactive metabolite (9-carboxymethoxymethylguanine). Biliary/fecal: <2%.
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category A/B
Category C
Antiviral
Antiviral